TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02508246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study: NCT03217682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Massage therapy sessions
Study: NCT03599973

Intervention type: OTHER
Group type: OTHER
Intervention: Plasmalyte A Viaflo
Description: Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
Study: NCT01688687

Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Study: NCT00415077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MMC PRK
Description: mitomycin C PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASEK
Description: LASEK
Study: NCT04041011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316
Description: 1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316
Description: 2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion
Description: 3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
Study: NCT01993173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)
Description: 0.5 mL, Intramuscular
Study: NCT03715179

Intervention type: DEVICE
Intervention: Ostomy Pouching System
Description: An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder), specifically from a stoma. No intervention is administered during the course of this study.
Study: NCT03510585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline and sniffing
Description: This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sniffing
Description: This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
Study: NCT00477321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT 107
Description: 3 dose levels: 3, 10 and 20µg/kg/week.3administrations
Study: NCT01449136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibacterial cement
Description: Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
Study: NCT00705861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a substitute of SK3530 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK3530
Description: SK3530 100mg
Study: NCT00767416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-559
Description: Cohort 1 (5 to \<24 months): N=80 MEDI-559 at 10\^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10\^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1 (5 to \< 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
Study: NCT03047304

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trans abdominal sonography
Description: Trans abdominal sonography in order to measure fetal PR interval.
Study: NCT04618445

Intervention type: BEHAVIORAL
Intervention: some risk factors that might be correlated with TMD
Description: Fonesca questionnaire
Study: NCT00391131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgNextGen 16%
Description: IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
Study: NCT01274832

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation of STN in Parkinsonian patients

Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation of STN in Parkinsonian patients
Study: NCT00807287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal tube placement using the unguided frictional method
Description: The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal tube placement using the endoscopic method
Description: Jejunal feeding tubes are placed using endoscopy
Study: NCT02775695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
Study: NCT04062487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality technology
Description: combine image with real body
Study: NCT04421183

Intervention type: DIAGNOSTIC_TEST
Intervention: draw blood
Description: draw blood from the all of patients

Intervention type: DIAGNOSTIC_TEST
Intervention: draw blood
Description: draw blood from the all of patients

Intervention type: DIAGNOSTIC_TEST
Intervention: draw blood
Description: draw blood from the all of patients

Intervention type: DIAGNOSTIC_TEST
Intervention: draw blood
Description: draw blood from the all of patients
Study: NCT02682745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
Study: NCT03573882

Intervention type: DRUG
Group type: OTHER
Intervention: Voxelotor
Description: 300mg or 500mg Tablet, Oral, With or Without Food
Study: NCT04431479

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04166006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: 7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
Study: NCT02682745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration
Study: NCT01116102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
Study: NCT01781507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine is an antihistamine currently indicated for allergic rhinitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo ( sugar pill) will provide the negative control for this study
Study: NCT01992393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIME
Description: TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
Study: NCT02277041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
Study: NCT00652210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiphoton microscopy
Description: Use of multiphoton microscopy to diagnose cancer
Study: NCT03525379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
Study: NCT04094285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAUERSTOFF
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAUERSTOFF
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STICKSTOFF
Description: STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STICKSTOFF
Description: STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes
Study: NCT03376880

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.

Intervention type: OTHER
Intervention: 1 year follow-up testing
Description: The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
Study: NCT00400179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1/Cisplatin
Description: In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/cisplatin
Description: In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
Study: NCT00693407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric capsaicin with heterotopic stimulation/ distraction
Description: The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric capsaicin with heterotopic stimulation/ distraction
Description: The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.
Study: NCT00005800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
Study: NCT03016156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRADLE
Description: A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRADLE
Description: A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRADLE
Description: A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red reflex testing
Description: Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red reflex testing
Description: Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
Study: NCT04519164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: mineralocorticoid receptor antagonist and potassium-sparing diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone with potassium chloride
Description: potassium-wasting diuretic with potassium chloride